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Abstract
Chronic Hepatitis C can progress to end-stage liver cirrhosis or hepatocellular carcinoma.
Interferon (IFN) therapy is effective in clearing the hepatitis C virus and in improving liver histol-
ogy, however, few patients maintain a sustained response (SR) after IFN withdrawal. Immediate
retreatment with IFN is therefore considered to be both effective and necessary, especially for pa-
tients who do not respond to the initial course of IFN therapy. All 145 patients included in the
present study underwent liver biopsy, followed by a first treatment course with various IFNs (al-
pha2a, alpha2b, alpha, OIF or beta). If hepatitis C virus (HCV) RNA was positive after the first
treatment, the patient was assigned to one of 3 groups, depending on whether his or her alanine
transaminase (ALT)level was normalized (incomplete response, IR), partially responsive(PR), or
non-responsive (NR). After an observational interval of 6 to 76 months, a second IFN treatment
was initiated with a higher dose or the same dose of the same IFN for the IR group, and with
a different IFN for the PR and NR groups. At 6 months after retreatment with IFN, the overall
efficacy of the retreatment was 29.7.% In the case of the IR group, who received the same IFN, the
overall efficacy was 45.2%. In patients identified as non-SR after the first treatment, who received
a different type of IFN for retreatment, the overall efficacy was 18.6%. Anti-IFN antibody was not
detected in most of the breakthrough cases. For some IR patients, retreatment with the same IFN
was effective. Anti-IFN antibody was mostly negative, indicating that the same IFN can be used in
both the first treatment and retreatment to obtain an SR. Switching to a different IFN was effective
for some PR and NR patients, suggesting that changing IFN for such cases is a good therapeutic
choice.
KEYWORDS: chronic hepatitis C, HCV RNA, breakthrough, IFN anitibody, retreatment with
IFN
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Chronic Hepatitis C can progress to end-stage liver cirrhosis or hepatocellular carcinoma. Interfer-
on (IFN) therapy is eﬀective in clearing the hepatitis C virus and in improving liver histology,
however, few patients maintain a sustained response (SR) after IFN withdrawal. Immediate retreatment with IFN is therefore considered to be both eﬀective and necessary, especially for patients who do not respond to the initial course of IFN therapy. All 145 patients included in the present study underwent liver biopsy, followed by a ﬁrst treatment course with various IFNs(α2a,
α2b, α, OIF orβ). If hepatitis C virus (HCV)RNA was positive after the ﬁrst treatment, the patient was assigned to one of 3 groups, depending on whether his or her alanine transaminase
(ALT)level was normalized(incomplete response, IR), partially responsive(PR), or non-responsive
(NR). After an observational interval of 6 to 76 months, a second IFN treatment was initiated with a higher dose or the same dose of the same IFN for the IR group, and with a diﬀerent IFN for the PR and NR groups. At 6 months after retreatment with IFN, the overall eﬃcacy of the retreat-
ment was 29.7 . In the case of the IR group, who received the same IFN, the overall eﬃcacy was 45.2 . In patients identiﬁed as non-SR after the ﬁrst treatment, who received a diﬀerent type of IFN for retreatment, the overall eﬃcacy was 18.6 . Anti-IFN antibody was not detected in most of the breakthrough cases. For some IR patients, retreatment with the same IFN was eﬀective.
Anti-IFN antibody was mostly negative, indicating that the same IFN can be used in both the ﬁrst treatment and retreatment to obtain an SR. Switching to a diﬀerent IFN was eﬀective for some PR and NR patients, suggesting that changing IFN for such cases is a good therapeutic choice.
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T he treatment of chronic hepatitis C is a challenge for most hepatologists because it can easily prog-
ress to end-stage liver cirrhosis or hepatocellular car-
cinoma. Since the ﬁrst discovery of Interferon(IFN)-α,
a cytokine produced after stimulation of leukocytes or ﬁbroblasts with virus infection or nucleotide treatment,
growing numbers of subtypes of IFN have been identiﬁed
［1］. Of these, IFN-α and IFN-βspecies have been used in the treatment of hepatitis. IFN therapy is an eﬀective method of clearing the hepatitis C virus(HCV)
from serum, normalizing biochemical liver function and improving liver histology in chronic hepatitis C patients.
Nevertheless, only about 40 of patients respond to this therapy and up to 60  of responders show reactivation of the disease after IFN withdrawal［2-4］. In some cases the disease even reactivates during treatment, thus leading to‘breakthrough’status (BT). This lowers the
 
Received September 11,2002;accepted January 23,2003.
?Corresponding author. Present Adderss:West Fukuyama Hospital, 340-1 Matsunaga-cho,Fukuyama-shi,Hiroshima 729-0104,Japan Phone:＋81-84-933-2110;Fax:＋81-84-934-0043 E-mail:egusanfh＠axel.ocn.ne.jp(K.Egusa)
http://www.lib.okayama-u.ac.jp/www/acta/
Acta Med. Okayama, 2003 Vol. 57, No. 3, pp. 151-158
 
Original Article
 
Copyright?ｃ2003 by Okayama University Medical School.
1
Egusa and Kondo: Efficacy of interferon retreatment on interferon-resistant
Produced by The Berkeley Electronic Press, 2003
ratio of sustained response (SR) to below 20 , as deﬁned by normal serum alanine transaminase (ALT)
levels and undetectable HCV RNA levels at 6 to 12 months after the end of therapy［3-6］. Immediate retreatment with IFN is therefore considered to be eﬀective and necessary especially for patients who do not respond to the initial course of IFN therapy or who suﬀer a relapse of the disease. This refractoriness may be due to the acquisition of resistance to the therapy (e.g.
occurrence of anti-IFN antibody, etc.), or from a total lack of response to IFN［7, 8］. Although controversial,
some reports suggest a possible correlation between anti-IFN antibody and the incidence of breakthrough［6-
9］. Retreatment with the same IFN could therefore possibly result in another failure to respond. Thus, it is naturally speculated that the usage of diﬀerent types of IFN may be beneﬁcial for retreatment of non-responders
(NR). On the other hand, growing numbers of reports suggest that some NR or relapsing patients can be successfully treated with a second cycle of the same IFN
［10-12］. Previous studies show that the SR rate for retreated patients with a 6-month course of IFN-αis 20 to 40  in cases of relapsers［10, 11, 13, 14］, up to 40  in cases of BT［14, 15］, and 0  to 17  in cases of NR without BT［11, 14, 15］. These numbers vary depending on the regimen, but overall, a longer duration of retreatment and a higher dosage of IFN produces a higher SR rate［10, 11, 14］.
In most of these studies, the patients were treated with IFN-α;thus, the question remains about the eﬃcacy of switching the type of IFN between the ﬁrst and second treatments. In the present study, therefore, we analyzed data from patients treated with IFN-α(recom-
binant and native), IFN-β, and Natural human IFN-α
Otsuka(OIF)to investigate the eﬀectiveness of each IFN for retreatment. Furthermore, most previous studies do not report detailed criteria for categorizing patients based on the ﬁrst treatment cycle. However, we consider this detailed analysis to be valuable since the prediction of eﬃcacy of retreatment is essential to be able to judge the applicability of the treatment. In the present study, we assigned patients to one of 3 groups based on their response to the ﬁrst treatment:IR(incomplete response),
PR(partial response)or NR(no response);patients were also identiﬁed according to whether or not they suﬀered a breakthrough(Table 1).
Previous studies have shown that a therapy that combines IFN-α and ribavirin, an anti-viral agent,
results in an improved response in both initial treatment and retreatment［16, 17］. Depending on the regimen,
however, increased adverse eﬀects from the combination therapy also increases the number of patients discontinu-
ing therapy［16］. Furthermore, although combination therapy is the most eﬀective in cases of HCV-1b hepatitis,
IFN-αalone has been found to be superior in some cases
［17］. Finally, the medical cost of combination therapy is signiﬁcantly higher than that of IFN therapy alone. Thus,
IFN therapy alone must be maintained as an option for patients with poor tolerance, patients with a particular genotype of HCV and patients for whom cost is an issue.
Methods
 
This retrospective cohort study includ-
ed 145 patients who were admitted to our hospital from 1988 through 2000. All had a well-established diagnosis
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Table 1  Assessment of response to treatment
 
Criteria  Definition
 
Abbreviation  Nomenclature  HCV-RNA at 6 months after treatment  ALT at 6 months after treatment
 
SR  Sustained response  Negative IR  Incomplete response  Positive  Normalized
 
PR  Partial response  Positive  Less than double of upper limit of normal range.
NR  No response  Positive  No change in ALT level
 
BT  Breakthrough  Once cleared,but reappears during treatment  
Once normalized,but relapses dur ing treatment
-
ETR  End of treatment response  Cleared at the end of treatment  Normalized at the end of treatment
 
The response to the treatment is assessed by both serum HCV-RNA and serum ALT level at 6 months after treatment.
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of chronic hepatitis C conﬁrmed by liver biopsy and positive HCV antibody test. Prior to treatment, other liver diseases were excluded by appropriate medical history and physical and laboratory data including negative HBsAg and ceruloplasmin levels.
The baseline laboratory parameters were measured,
including the mean serum ALT, albumin, alkaline phos-
phatase, and bilirubin levels, prothrombin time, and partial thromboplastin time. Serum levels of total bilirubin were＜2.0 mg/dl for all patients, and serum levels of albumin were ＞3.0 g/dl. Clinically detectable ascites,
edema, and encephalopathy were absent in all patients.
All patients gave their written or oral informed consent prior to treatment.
Recombinant IFN-α2b was obtained from Schering-Plough, Inc. (Osaka, Japan), recombinant IFN-α2a was obtained from Hoﬀmann-La Roche, Inc.
(Nutley, NJ, USA), IFN-α was obtained from Sumitomo Pharmaceuticals, Inc. (Osaka, Japan), IFN-
βwas obtained from Kanebo Ltd. (Tokyo, Japan), and IFN-OIF was obtained from Otsuka Pharmaceutical Factory, Inc. (Tokushima, Japan). In the present study,
both recombinant IFN (α2a, α2b)and native IFN (α,
β, OIF)were used (Table 2). IFN-α2a, IFN-α2b,
IFN-α, and IFN-OIF were injected intramuscularly for 24 weeks, and IFN-βwas administered by intravenous injection for 6 weeks.
All 145 patients, who had under-
gone liver biopsy, underwent a ﬁrst treatment course with one of the IFN subtypes (α2a, α2b, α, OIF orβ).
During the ﬁrst IFN cycle, which lasted 6 weeks to 6 months, the patients received either 3, 5, 6 or 10 MIU of the appropriate IFN 3 times per week. After 6 to 76 months of observation, a second IFN treatment was started at a higher dose or at the same dose of the same
 
IFN to IR patients, or with a change to a diﬀerent IFN for NR and PR patients;patients who achieved SR did not receive a second treatment (Fig. 1). During the second course of IFN treatment, the patients received either 3, 5, 6, 10 or 14 MIU IFN 3 times per week for 6 weeks to 6 months(Tables 2 and 3).
Laboratory tests were performed in the clinical laboratories of our medical
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Table 2  Administration of IFN
 
IFN  Dose(MIU/week) M/iv  Duration(weeks)
α2a r  9  M  24
α2b r  30  M  24
α n  18  M  24 OIF n  15  M  24
β n  42  iv  6
 
The choice of IFN for treatment is shown. iv, intravenous injection;
M, intra-muscular injection;n, native IFN;OIF, natural IFN-α
provided Otsuka pharmaceuticals Co., Ltd., Tokyo, Japan;r, recom-
binant IFN.
Fig.1  Study design-description of cohort groups. A total of 145 patients were primarily treated with various types of IFN. The patients were assigned to one of 4 groups (SR, IR, PR or NR)
depending on their response to the primary treatment. The cohort groups for the secondary treatment consisted only of the non-SR groups(IR, PR and NR). 16 non-SR patients did not receive a second treatment.
Table 3  Regimen for IFN choice
 
Primary regimen  Secondary regimen
α2a
(11)
α2a (1)
α2b (8)
α (2)
α2b
(35)
α2a (3)
α2b (28)
α (4)
α
(12)
α2b (10)
α (2)
OIF
(9)
α2a (2)
α2b (4)
α (2)
β (1)
β
(7)
α2b (4)
α (1)
OIF (2)
The combination of IFNs for the ﬁrst and the second treatment is shown. The numbers in parentheses represent patients per group.
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center using standard methods. Pre-and post-treatment liver biopsies were evaluated in a blinded fashion. The method of histopathological evaluation followed the classiﬁcations previously described［18］.
The baseline serum HCV RNA concentration for each patient was calculated as the mean of the HCV RNA concentrations during screening.
Serum HCV RNA concentration was determined at weeks 8, 16, 24, 28, 38, 48 and 72 in the 24-week retreatment group and at weeks 4, 6, 10, 18, 30 and 54 in the 6-week retreatment group. Serum HCV RNA was determined by the quantitative multicycle reverse transcription-polymerase chain reaction (RT-PCR)
method［19］. The assays were performed at an indepen-
dent research institute by technicians who were blinded to the patients’treatment.
HCV genotypes and subtypes were identiﬁed by the PCR method described by Ohno
［20］. Brieﬂy, primers complementary to the conserved sequences of the 5’untranslated region of HCV genomes of the diﬀerent genotypes were used in the RT-PCR reactions. HCV RNA was extracted from the patients’
sera and ampliﬁed by RT-PCR for the ﬁrst round of ampliﬁcation. The samples were ampliﬁed again with another set of primers using the nested-PCR method.
The ampliﬁed fragments from the second round of PCR were subcloned into TA cloning vector for sequencing.
Genotyping of the viruses was then conducted according to the obtained sequences［20］.
The eﬃcacy of the primary treatment was assessed at 6 months after treatment according to the criteria estab-
lished by the Japanese Ministry of Health and Welfare and those described byYano［21］(Table 1). An HCV RNA responder was deﬁned as a patient with 2 consecu-
tive undetectable (＜100 copies/ml) values. If HCV RNA remained negative for 6 months, the patient was assigned to the SR group and did not undergo a second treatment. If HCV RNA was positive, the patient was assigned to the IR or PR group, depending on whether his or her ALT was normalized or partially responsive,
respectively. ALT response was deﬁned as 2 consecutive normal ALT values(≦48 U/L);ALT was measured at the end of the 24-week treatment period and again at the end of the 24-week post-treatment observation period.
Partial ALT response was deﬁned as a reduction of ALT level to less than double the upper limit of the normal range. If neither HCV RNA nor ALT showed any
 
response, the patient was assigned to the NR group. If HCV RNA was negative at the end of the 6-week or 6-month treatment, the patient was deﬁned as ETR(end of treatment response). If HCV RNA reappeared during treatment, the patient was deﬁned as BT.
Anti-IFN antibody was measured by biological neutralization assays (SRL,
Hachioji, Japan). In brief, a series of IFN-antiserum mixtures were prepared containing varying dilutions of antiserum. The mixtures were incubated for 1 at 37°C,
and placed on the assay cells for observation of antiviral eﬀect. The neutralization titer was measured by compari-
son to the control assay which did not include antiserum.
Noncontinuous variables,
such as analyses of eﬃcacy of treatment and comparison of patients’background, were assessed byχ?-test or Fisher’s exact probability test. Statistical comparison between the SR and non-SR groups concerning the age of the patients, months from 1st treatment and ALT upon initiation of retreatment were assessed by Mann-Whitney U Test. P＜0.05 was considered to be signiﬁcant
 
Results
 
After primary treatment with IFN, 55 of 145 patients
(37.9 ) achieved SR. Of the 90 patients who were resistant to IFN (NR, IR and PR), 74 fulﬁlled the requirements for secondary treatment:31 cases of IR,
43 cases of PR or NR. The overall rate of SR after secondary treatment with IFN was 29.7 (22/74)and that of non-SR was 70.3 (52/74, Table 4).
The side eﬀects of IFN retreatment requiring reduction of therapy were fatigue and fever in 2 patients, headache in 2, depression in 1, psychological eﬀects in 4, skin rash
 
Table 4  Eﬃcacy of the primary treatment and the secondary treatment
 
Treatment  Total patient number  SR  IR  PR  NR
 
Primary  145  55(37.9%) 36(31)
33
(29)
21
(14)
Secondary  74  22(29.7%) 17  24  11
 
Of primary treatment, 16 patients did not receive secondly treatment because of their disinclination. ( ), cases received second treat-
ment.
Egusa et al. Acta Med. Okayama Vol. 57, No. 3 154
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in 1, anemia and leukopenia in 1, hypothyroidism in 1,
elevated serum/urine amylase in 3, aggravation of diabetes mellitus in 2, interstitial pneumonitis in 1, and proteinuria in 1. Although retreatment was reduced in these cases, none of these patients ceased retreatment due to side eﬀects of the IFN.
Analysis of the patients’background showed no signiﬁcant diﬀerence in age between those who achieved SR and those who were deﬁned as non-SR with retreat-
ment (Table 5). Likewise, the levels of ALT of these groups at the start of retreatment were not signiﬁcantly diﬀerent. We next analyzed the stages and grades of the SR and non-SR groups according to Desmet’s classiﬁcation of chronic hepatitis［22］. The occurrence of stage 0 and stage 1(S0 and S1), or that of grade 0 and grade 1 (G0 and G1) was not signiﬁcantly diﬀerent between the SR and non-SR groups (Table 5). The number of patients with a low level of HCV RNA(＜100 Kcp/ml)was 5 of 22(22.7 )in the SR group and 5 of 52(9.6 )in the non-SR group and there was no statisti-
cal diﬀerence. The number of patients with a high total dose(＞400 MU)was also not signiﬁcantly diﬀerent. The ratio of patients whose response to the primary treatment was IR was signiﬁcantly higher in the secondary SR group(14 of 22)than that of patients in the secondary non-SR group(17 of 52).
The choice of IFN did not produce any signiﬁcant eﬀect on the overall response to the secondary treatment:
SR group (IFN-recombinantα/nativeα/β＝17/5/0)
vs. non-SR group(29/16/7). When the ratio of patients with HCV-1b was compared between the SR group and the non-SR group, there was a signiﬁcantly higher number of such patients in the non-SR group:10 of 22
(45.5 )in the SR group vs. 37 of 52 (71.5 )in the non-SR group(Table 5).
The sera from 13 patients who were designated NR upon ETR were tested for IFN antibody. When analyzed after primary treatment, 1 patient of the 13 was positive for anti-IFN antibody. It is of note, however, that this patient also fell into the NR group after retreatment.
The eﬃcacy of diﬀerent combi-
nations of IFN was compared(Table 6). In the primary IFN-α2a non-SR patients, eﬃcacy was found to be 0 for retreatment with IFN-α2a and 30 (3/10)with a diﬀerent IFN (α2b, α). In the primary IFN-α2b non-SR patients, eﬃcacy was 50 (14/28)with IFN-
α2b retreatment and 0 (0/7)with a diﬀerent IFN(α2a,
α). In the primary IFN-αnon-SR patients, eﬃcacy was 0 (0/2)with IFN-αand 20 (2/10)with a diﬀerent IFN (α2b). In the primary IFN-β non-SR patients,
eﬃcacy was 0 (0/7)with a diﬀerent IFN (α2b, α,
OIF). And ﬁnally, in the primary OIF non-SR patients,
eﬃcacy was 33 (3/9)with a diﬀerent IFN(α2a,α2b,
α, β).
Eﬃcacy was compared between patients who were treated with the same type of IFN for both the primary and the secondary treatments, and between patients who
 
Table 5  Background of patients for the secondary treatment
 
Response to IFN
 
SR(N＝22) non-SR(N＝52)
Age of patients (y/o)(M±SD) 53.3±7.0  59.0±9.3 Low HCV-RNA cases (＜100 Kcp/ml) 5/22(22.7%) 5/52( 9.6%)
Ratio of HCV subtype 1b  10/22(45.5%)? 37/52(71.2%)?
Initial NR  3/22(13.6%) 11/52(21.2%)
Initial PR  5/22(22.7%) 24/52(46.2%)
Initial IR  14/22(63.6%)? 17/52(32.7%)?
Total dose(＞400 MU) 20/22(90.9%) 45/52(86.5%)
Months from 1st treatment(M±SD) 27.8±24.7  37.8±31.8 ALT at the start of re-treatment(M±SD) 69.8±52.3  58.2±44.4
(S0＋S1)/total  2/22( 9.1%) 5/52( 9.6%)
(G0＋G1)/total  1/22(4.5%) 2/52(3.8%)
The background of patients is compared between SR group and Non-SR group.
S0＋S1, Staging 0＋Staging 1;G0＋G1, Grading 0＋Grading 1［22］. ?P＜0.05.
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 received diﬀerent IFN’s in the 2 treatments(“switched”).
The eﬃcacy of the group with the same IFN was 45.2 ,
and that of the switched group was 18.6 , a statistically signiﬁcant diﬀerence(P＜0.05)(Table 7). An analysis of patients who received the same IFN in both treatments showed that the eﬃcacy of the secondary treatment was highest (50 )in those patients who received IFN-α2b for both treatments.
We also analyzed the eﬃcacy of the secondary treatment by dividing the patients into IR, PR and NR groups, with subgroups based on whether they suﬀered a breakthrough during the primary treatment(Fig. 2). In the breakthrough group in particular, the IR patients showed a higher response ratio for the secondary treatment(50 , 3/6)than either PR or NR patients(0 , 0/7)although there was no statisti-
cal signiﬁcance(P＝0.070). The overall eﬃcacy of the secondary treatment was 23.1 (3/13)among patients who suﬀered a breakthrough and 31.1 (19/61)with those who did not.
Discussion
 
There is no doubt that IFN plays an important role in the treatment of chronic hepatitis C［23］. Recently,
remarkable eﬀorts have been made to improve the SR rate for initial treatment, and in the case of relapsers or non-responders, to successfully retreat them. There have been many attempts with successful results, such as combination therapy with the anti-viral reagent, ribavirin,
and treatments involving a change of IFN administration to a higher dosage and/or a longer duration. A further approach is to switch the type of IFN in patients who did not respond to the primary treatment.
Prediction of IFN responsiveness based on the patient’s background is beneﬁcial in terms of choosing the most appropriate therapeutic approach. Previous reports have shown that the rate of response diﬀers among HCV genotypes［12, 24］. These studies show that genotype 1b tends to be somewhat resistant to IFN-α. In the present retrospective study, the number of patients with HCV-1b was signiﬁcantly higher in the non-SR group than in the SR group, indicating that the higher resistance of HCV-1b seems to remain in eﬀect for the secondary
 
Table 6  Eﬃcacy of the secondary treatment
 
Primary treatment
 
Re
-tr
ea
tm
en
t  IFN
α2a
α2b
α
β
OIF
α2a 0/1 2/8(25%)
1/2(50%)
―
―
α2b 0/3 14/28 (50%) ?
0/4
―
―
α
―
2/10(20%)
0/2
―
―
β
―
0/4 0/1
―
0/2
 
OIF 1/2(50%)
0/4 1/2(50%)
1/1
―
The numbers represent numbers of SR cases/numbers of patients. The numbers in parentheses are percentage. ―, No data.?P＜0.05.
Table 7  Comparison of eﬃcacy between identical IFN and switched IFN
 
Type of IFN for the secondary treatment  Total case  SR case  SR ratio
 
Same IFN  31  14  45.2% ?IFN Switched  43  8  18.6%
Comparison of eﬃcacy between groups where identical IFN is used and where IFN types are switched. ?P＜0.05.
Fig.2  SR ratio after the secondary treatment in breakthrough and non-breakthrough groups. Dark columns indicate breakthrough (＋)
groups. White columns indicate non-breakthrough(－)groups.
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treatment.
Previous studies have indicated that a higher dosage and/or a longer duration of IFN therapy can improve the SR rate［25-27］, although such treatments may entail negative consequences such as higher costs and a higher occurrence of adverse eﬀects. Our data also suggest a positive correlation between a higher total dosage of IFN and the SR rate, but we have so far failed to detect any statistically signiﬁcant eﬀect of a higher total dose in improving outcome(Table 5). In order to conﬁrm the beneﬁcial eﬀects of a higher total dose, either a larger patient group or a diﬀerent analytical method may be necessary. For example, various IFN susceptibility factors of both host and viral contributions have been reported［4, 14］. With the advent of genetic analysis in clinical medicine, as yet unknown factors might be identiﬁed including viral gene variation for drug resistance or host genetic polymorphism by single nucleotide polymorphism analysis. If subcategorization of treatment depending on such factors becomes available, it may provide important and beneﬁcial insight.
In a previous study, patients assigned to the NR group after primary treatment and retreated with the same type of IFN have shown an eﬃcacy ranging from 0 to 17 , depending on the regimen［6］. The present study,
using 6 weeks or 6 months of administration of the same type of IFN or a diﬀerent type of IFN, shows a 45.2 and 18.6  SR rate, respectively(Table 7), which is statistically signiﬁcant and furthermore, is considered to be a remarkable result. It is possible that the higher eﬃcacy in the group treated with the same IFN may not necessarily be due to the superiority of the same-IFN protocol, but rather to the fact that this group represents the primary IR group, while the other group consists of NR and PR patients. This is compatible with the ten-
dency of IR breakthrough patients to show a better response than NR or PR patients (Fig. 2, P＝0.070).
There are controversial arguments about the involve-
ment of anti-IFN antibodies in non-responding or break-
through cases. Some previous studies provide evidence suggesting that anti-IFN antibody is associated with the incidence of breakthrough［6-9］. On the other hand,
there are also reports denying any correlation between the occurrence of anti-IFN antibody and breakthrough or failure to respond［15, 28, 29］. The discussion of the involvement of an anti-IFN antibody raises some technical questions about detection methods. If ELISA is used for the detection of anti-IFN antibody, 2 things must be
 
taken into consideration. First, if IFN is immobilized onto the ELISA plate, the conjugation of IFN itself may sacriﬁce the epitope against anti-IFN antibody in the sample. Second, if sandwich ELISA is used, in cases where the 2 antibodies share the same portion of the epitope, this may also result in a masking of the epitope and consequently in a false negative result. To avoid these problems, we used a bioassay method to detect anti-IFN antibody. Our study shows that most of the non-responsive cases are not associated with anti-IFN antibody, although 1 patient of 13 cases did give a positive result for anti-IFN antibody. In fact, nearly half of the non-SR cases, as in many other reports［6-9］,
showed a good response to retreatment with the same IFN. Thus, anti-IFN antibody is not necessarily a major cause of non-responsiveness. It is worth bearing in mind,
however, that the 1 patient who was positive for anti-IFN antibody after the primary treatment was assigned to the NR group after the retreatment.
In conclusion, our study suggests that retreatment with IFN alone is eﬀective for some patients, especially when they are designated as IR after an observation period (Table 5). For such patients, retreatment with IFN-α2b is eﬀective, especially when the primary treat-
ment was also with IFN-α2b. We also suggest that in some cases it is eﬀective to switch the type of IFN for non-SR patients since 18.6  of non-SR patients in the present study responded well to such a regimen. Addi-
tional studies with a greater number of cases are neces-
sary, however, for statistical conﬁrmation of this ﬁnding.
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